{"id":"hydroxyurea-hu","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (anemia, leukopenia, thrombocytopenia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Elevated uric acid (tumor lysis)"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Skin hyperpigmentation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking the enzyme ribonucleotide reductase, hydroxyurea depletes the deoxyribonucleotide pool required for DNA synthesis, thereby slowing or halting cell division. In sickle cell disease, it also increases fetal hemoglobin (HbF) production, which inhibits polymerization of sickle hemoglobin and reduces hemolysis. This dual mechanism makes it useful in both oncology and hematologic disorders.","oneSentence":"Hydroxyurea inhibits ribonucleotide reductase, reducing deoxyribonucleotide synthesis and slowing DNA replication in rapidly dividing cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:55:09.471Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML)"},{"name":"Sickle cell disease (to reduce vaso-occlusive crises)"},{"name":"Polycythemia vera"},{"name":"Essential thrombocythemia"}]},"trialDetails":[{"nctId":"NCT06093672","phase":"PHASE3","title":"Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera","status":"RECRUITING","sponsor":"Italfarmaco","startDate":"2024-03-26","conditions":"Polycythemia Vera","enrollment":220},{"nctId":"NCT05853458","phase":"PHASE4","title":"Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2023-07-28","conditions":"Polycythemia Vera","enrollment":76},{"nctId":"NCT06979492","phase":"PHASE4","title":"Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease","status":"RECRUITING","sponsor":"Emory University","startDate":"2026-04","conditions":"Sickle Cell Disease, Pregnancy Related","enrollment":50},{"nctId":"NCT05405114","phase":"PHASE2","title":"Research Study Investigating How Well NDec Works in People With Sickle Cell Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-07-07","conditions":"Sickle Cell Disease","enrollment":96},{"nctId":"NCT07292259","phase":"PHASE2","title":"Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia","status":"RECRUITING","sponsor":"Pakistan Blood and Marrow Transplant (PBMT) Group","startDate":"2024-01-01","conditions":"Transfusion Dependent Beta Thalassemia","enrollment":150},{"nctId":"NCT02158858","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies","status":"COMPLETED","sponsor":"Constellation Pharmaceuticals","startDate":"2014-07-16","conditions":"Myelofibrosis, Leukemia, Myelocytic, Acute, Myelodysplastic/Myeloproliferative Neoplasm","enrollment":336},{"nctId":"NCT07170592","phase":"PHASE1","title":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients","status":"NOT_YET_RECRUITING","sponsor":"Bionoxx Inc.","startDate":"2025-12","conditions":"Treatment-Refractory Solid Tumors","enrollment":24},{"nctId":"NCT07190833","phase":"PHASE1","title":"A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)","status":"NOT_YET_RECRUITING","sponsor":"Bionoxx Inc.","startDate":"2025-11","conditions":"Treatment-Refractory Solid Tumors","enrollment":27},{"nctId":"NCT05953584","phase":"PHASE2","title":"A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke","status":"RECRUITING","sponsor":"Forma Therapeutics, Inc.","startDate":"2023-06-20","conditions":"Sickle Cell Disease","enrollment":27},{"nctId":"NCT03653338","phase":"PHASE1, PHASE2","title":"T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias","status":"RECRUITING","sponsor":"Paul Szabolcs","startDate":"2018-08-02","conditions":"Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia","enrollment":5},{"nctId":"NCT05485948","phase":"PHASE2","title":"A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU","status":"ACTIVE_NOT_RECRUITING","sponsor":"PharmaEssentia","startDate":"2021-10-08","conditions":"Polycythemia Vera","enrollment":49},{"nctId":"NCT06199557","phase":"PHASE1, PHASE2","title":"A Study to Investigate Treatment of HU and VPA, or 6-MP and VPA in Unfit AML/HR-MDS Patients","status":"RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2024-05-23","conditions":"Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes, Adult","enrollment":48},{"nctId":"NCT03442114","phase":"NA","title":"Shared-Decision Making for Hydroxyurea","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-07-12","conditions":"Sickle Cell Anemia, Children, Only","enrollment":176},{"nctId":"NCT06490601","phase":"PHASE2","title":"Long Term Beta Thalassemia Treatment: Findings From The Extension Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2022-04-01","conditions":"Fetal Hemoglobin, Beta-Thalassemia, Hemoglobinopathies","enrollment":30},{"nctId":"NCT03263559","phase":"PHASE2","title":"Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2017-10-03","conditions":"Sickle Cell Disease","enrollment":95},{"nctId":"NCT06464458","phase":"NA","title":"Optimizing the Management of Sickle Cell Patients on Hydroxyurea: The Value of Therapeutic Pharmacological Monitoring","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2023-02-08","conditions":"Sickle Cell Disease","enrollment":30},{"nctId":"NCT06761560","phase":"PHASE2, PHASE3","title":"Optimizing Hydroxyurea Dosage With Pharmakokinetic in Patients Suffering of Moderate to Severe Sickle Cell Anemia","status":"NOT_YET_RECRUITING","sponsor":"Yves Pastore","startDate":"2025-01-15","conditions":"Sickle Cell Disease (SCD)","enrollment":29},{"nctId":"NCT04691323","phase":"NA","title":"The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2021-03-02","conditions":"Sickle Cell Disease, Sickle B+ Thalassemia, Sickle Beta Zero Thalassemia","enrollment":68},{"nctId":"NCT04053764","phase":"PHASE2","title":"Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-12-10","conditions":"Sickle Cell Disease (SCD)","enrollment":58},{"nctId":"NCT02258659","phase":"PHASE2","title":"Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-09-22","conditions":"Human Papilloma Virus Infection, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Oropharynx","enrollment":62},{"nctId":"NCT04707235","phase":"","title":"ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Theravia","startDate":"2020-08-21","conditions":"Sickle Cell Disease","enrollment":2093},{"nctId":"NCT03077542","phase":"PHASE1, PHASE2","title":"Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2017-04-06","conditions":"Sickle Cell Disease","enrollment":57},{"nctId":"NCT01847326","phase":"PHASE1","title":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2013-03-26","conditions":"Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx","enrollment":48},{"nctId":"NCT06503458","phase":"","title":"A Low-Interventional Study of an Electronic Sickle Cell Disease Patient Reported Outcomes in Sickle Cell Participants","status":"TERMINATED","sponsor":"Sanguine Biosciences","startDate":"2022-01-19","conditions":"Sickle Cell Disease, Sickle Cell Anemia","enrollment":52},{"nctId":"NCT04080167","phase":"NA","title":"Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-11-11","conditions":"Sickle Cell Disease","enrollment":382},{"nctId":"NCT02197845","phase":"NA","title":"Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2012-10","conditions":"Sickle Cell Disease","enrollment":353},{"nctId":"NCT05681598","phase":"NA","title":"Hydroxyurea Treatment for Adult Sickle Cell Anemia Patients in Kinshasa","status":"COMPLETED","sponsor":"University of Kinshasa","startDate":"2017-08-30","conditions":"Sickle-Cell Anaemia","enrollment":166},{"nctId":"NCT05421104","phase":"","title":"Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-11-27","conditions":"Polycythemia Vera (PV)","enrollment":1576},{"nctId":"NCT03825341","phase":"PHASE2","title":"Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-06-10","conditions":"Sickle Cell Disease, Thalassemia","enrollment":1},{"nctId":"NCT00000939","phase":"PHASE2","title":"A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT04675645","phase":"NA","title":"Adherence to HU and HRQOL in Patients With Sickle Cell Disease: An Intervention Study Using HU-Go App","status":"COMPLETED","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2018-05-15","conditions":"Sickle Cell Disease, Sickle B+ Thalassemia, Sickle Beta Zero Thalassemia","enrollment":33},{"nctId":"NCT02038036","phase":"PHASE3","title":"Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-03-25","conditions":"Polycythemia Vera","enrollment":149},{"nctId":"NCT03020615","phase":"PHASE2","title":"Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-05-12","conditions":"Sickle Cell Anemia","enrollment":58},{"nctId":"NCT01597401","phase":"PHASE1","title":"A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2012-05-12","conditions":"Sickle Cell Disease","enrollment":19},{"nctId":"NCT02252159","phase":"","title":"Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2014-07-31","conditions":"MPN (Myeloproliferative Neoplasms)","enrollment":2544},{"nctId":"NCT01801423","phase":"NA","title":"Sickle Cell Disease - Stroke Prevention in Nigeria Trial","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2013-04-24","conditions":"Sickle Cell Anemia, Sickle Cell Disease, Stroke","enrollment":29},{"nctId":"NCT02516579","phase":"","title":"European Sickle Cell Disease Cohort - Hydroxyurea","status":"COMPLETED","sponsor":"Theravia","startDate":"2009-01","conditions":"Sickle Cell Disease","enrollment":1906},{"nctId":"NCT00928707","phase":"PHASE2","title":"Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera","status":"COMPLETED","sponsor":"Italfarmaco","startDate":"2009-06","conditions":"Polycythemia Vera","enrollment":45},{"nctId":"NCT02225132","phase":"PHASE1, PHASE2","title":"Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2014-08-23","conditions":"Sickle Cell Disease","enrollment":10},{"nctId":"NCT03577691","phase":"NA","title":"Efficacy of a Decision Aid for Hydroxyurea in Sickle Cell Disease","status":"TERMINATED","sponsor":"Emory University","startDate":"2018-08-03","conditions":"Sickle Cell Disease","enrollment":2},{"nctId":"NCT00383448","phase":"PHASE2","title":"HSCT for High Risk Inherited Inborn Errors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-09","conditions":"Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy","enrollment":38},{"nctId":"NCT03111589","phase":"NA","title":"Monocytic Expression of Heme Oxidase-1 (HO-1) in Sickle Cell Patients and Correlation With the Humoral Immune Response to Vaccine and With Allo-immunization.","status":"COMPLETED","sponsor":"Francis Corazza","startDate":"2016-10","conditions":"Sickle Cell Disease","enrollment":102},{"nctId":"NCT03515018","phase":"PHASE3","title":"Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2018-05-01","conditions":"Leukemia, Chronic Myeloid","enrollment":60},{"nctId":"NCT01632904","phase":"PHASE3","title":"Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2012-06","conditions":"Polycythemia Vera","enrollment":110},{"nctId":"NCT02611973","phase":"PHASE3","title":"Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-03-10","conditions":"MPN, Essential Thrombocythemia","enrollment":2250},{"nctId":"NCT00143572","phase":"PHASE1","title":"Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2004-11","conditions":"Anemia, Sickle Cell","enrollment":16},{"nctId":"NCT01949805","phase":"PHASE3","title":"Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera","status":"COMPLETED","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2013-09","conditions":"Polycythemia Vera","enrollment":257},{"nctId":"NCT00387933","phase":"PHASE1","title":"Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma","status":"COMPLETED","sponsor":"Duke University","startDate":"2005-07","conditions":"Brain and Central Nervous System Tumors","enrollment":37},{"nctId":"NCT02480608","phase":"PHASE1, PHASE2","title":"Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)","status":"COMPLETED","sponsor":"University of Leipzig","startDate":"2004-04","conditions":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive","enrollment":113},{"nctId":"NCT01506544","phase":"PHASE1","title":"Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia","status":"COMPLETED","sponsor":"Children's Mercy Hospital Kansas City","startDate":"2011-12","conditions":"Sickle Cell Anemia","enrollment":39},{"nctId":"NCT00023959","phase":"PHASE1","title":"Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-07","conditions":"Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip","enrollment":39},{"nctId":"NCT00532883","phase":"PHASE2","title":"Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-01","conditions":"Hemoglobin SC Disease","enrollment":44},{"nctId":"NCT00336362","phase":"NA","title":"Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-07","conditions":"Beta-Thalassemia","enrollment":26},{"nctId":"NCT01645124","phase":"PHASE3","title":"Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)","status":"TERMINATED","sponsor":"Consorzio Mario Negri Sud","startDate":"2008-05","conditions":"Polycythemia Vera","enrollment":365},{"nctId":"NCT01624038","phase":"PHASE2, PHASE3","title":"Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin.","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2012-06","conditions":"Thalassemia Intermedia","enrollment":40},{"nctId":"NCT00290771","phase":"PHASE2","title":"Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)","status":"TERMINATED","sponsor":"Novartis","startDate":"2006-02","conditions":"Recurrent Glioblastoma Multiforme (GBM)","enrollment":231},{"nctId":"NCT00154375","phase":"PHASE3","title":"Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-10","conditions":"Glioblastoma Multiforme, Astrocytoma","enrollment":240},{"nctId":"NCT00002427","phase":"PHASE1","title":"Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults","status":"COMPLETED","sponsor":"Research Institute for Genetic and Human Therapy","startDate":"1999-05","conditions":"HIV Infections","enrollment":225}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2040,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Hydroxyurea (HU)","genericName":"Hydroxyurea (HU)","companyName":"Bionoxx Inc.","companyId":"bionoxx-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hydroxyurea inhibits ribonucleotide reductase, reducing deoxyribonucleotide synthesis and slowing DNA replication in rapidly dividing cells. Used for Chronic myeloid leukemia (CML), Sickle cell disease (to reduce vaso-occlusive crises), Polycythemia vera.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}